ERBB2 and breast carcinoma: Likewise, increased levels of microRNA-1246 and microRNA-155 in circulating exosomes from HER2-positive, transtuzumab-resistant breast cancer patients have been shown to be different from transtuzumab-resistant cases [79], raising the possibility of using the content of EVs in predicting the acquired therapeutic resistance.